Test d'insuline Dubaï — Insuline à jeun et HOMA-IR

The relationship between insulin resistance and metabolic disease is best understood as a progression along a spectrum. At one end lies optimal insulin sensitivity, where normal insulin levels efficiently signal glucose uptake into muscle, liver, and fat cells. As resistance develops, the pancreas compensates by secreting more insulin, maintaining normal glucose at the cost of chronically elevated insulin. This compensated hyperinsulinaemia is the early warning phase — clinically silent on glucose testing but measurable through fasting insulin and HOMA-IR. If left unaddressed, beta-cell exhaustion eventually occurs, compensation fails, and blood glucose rises into the prediabetic and then diabetic range.

The practical implication is that the optimal window for intervention through lifestyle change, dietary modification, and targeted supplementation or medication spans the years or decades of compensated insulin resistance before glucose abnormalities emerge. Identifying patients in this window through proactive HOMA-IR screening, particularly in high-risk groups including South Asians, those with family history, women with PCOS, and individuals with abdominal obesity, allows preventive strategies to be implemented with the greatest chance of sustained success. Regular HOMA-IR monitoring over time also provides an objective endpoint to measure treatment response, far more sensitive than HbA1c or fasting glucose in the early intervention phase.